Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Accelerated Phase Chronic Myelogenous Leukemia: early-phase trial registry
A small indexed set (12 trials) with no open enrollment listed right now.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · none currently recruiting · #1,429 of 28,707 conditions by registered trial count
Accelerated Phase Chronic Myelogenous Leukemia: 12 US clinical trials tracked, none currently recruiting.
Accelerated Phase Chronic Myelogenous Leukemia is the subject of 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Fred Hutchinson Cancer Center, running 4 of these trials.
Enrollment posture brief
Registry condition accelerated-phase-chronic-myelogenous-leukemia
OPEN 0 | RECR 0% | LATE 1 | EARLY 8 | RANK #1429 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Adenocarcinoma of the Gastroesophageal Junction (0% recruiting · 8 trials)
Accelerated Phase Chronic Myelogenous Leukemia has no open enrollment in this registry pull (12 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Accelerated Phase Chronic Myelogenous Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Accelerated Phase Chronic Myelogenous Leukemia is recruiting below its size-band peers.
0 of 12 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Accelerated Phase Chronic Myelogenous Leukemia research.
Fred Hutchinson Cancer Center accounts for 4 of 12 trials (33.3%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most Accelerated Phase Chronic Myelogenous Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 12 trials that report a genuine target (sentinel values excluded). 9 of those (75%) plan for fewer than 100 participants.
-
Accelerated Phase Chronic Myelogenous Leukemia research is mostly interventional.
11 interventional and 1 observational studies make up this index (91.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
12 total, page 1 of 1
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
City of Hope Medical Center
NCT01199562
Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia
Children's Oncology Group
NCT04258943
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
NCT00799461
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
Fred Hutchinson Cancer Center
NCT00489203
Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
NCT00054431
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
University of Chicago
NCT01839916
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Children's Oncology Group
NCT00309907
Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer
National Cancer Institute (NCI)
NCT00012376
A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies
Fred Hutchinson Cancer Center
NCT00343798
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT00408681
Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies
Nohla Therapeutics
NCT01175785
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
Fred Hutchinson Cancer Center
NCT00112593
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 5 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Accelerated Phase Chronic Myelogenous Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Accelerated Phase Chronic Myelogenous Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Accelerated Phase Chronic Myelogenous Leukemia page
12 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Accelerated Phase Chronic Myelogenous Leukemia trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Fred Hutchinson Cancer Center sponsors the most Accelerated Phase Chronic Myelogenous Leukemia trials on record, review their full trial history before evaluating a specific study. See Fred Hutchinson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Accelerated Phase Chronic Myelogenous Leukemia condition card totals 12 registered trials; most-linked intervention laboratory biomarker analysis; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.